Mylan sees opportunity in rival Teva’s weakness
January 09, 2018 at 21:12 PM EST
Challenging conditions in the U.S. generic drug market have hit drugmaker Teva Pharmaceutical Industries Ltd. particularly hard.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.